09:56 AM EST - Medicenna Therapeutics Corp. : Announced that an abstract evaluating survival outcomes with bizaxofusp (formerly MDNA55) in unresectable, IDH-wildtype recurrent glioblastoma (rGBM) has been selected for an oral presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026), taking place November 12-15, in Philadelphia. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $0.40.
